SCHEMBL21746957

SCHEMBL21746957

COC(=O)c1cnc(Cl)nc1C

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFKB1 P19838 4/20 0.55
NFKB2 Q00653 3/20 0.55
RELA Q04206 3/20 0.55
JUN P05412 2/20 0.55
XPO1 O14980 1/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
RAB9A P51151 3/20 0.49
NPC1 O15118 3/20 0.49
MAPT P10636 3/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
GAA P10253 1/20 0.42
CASP3 P42574 1/20 0.42
SENP8 Q96LD8 1/20 0.42
SENP7 Q9BQF6 1/20 0.42
SENP6 Q9GZR1 1/20 0.42
ATF1 P18846 1/20 0.41
NPSR1 Q6W5P4 1/20 0.40
KDM4E B2RXH2 1/20 0.40
TSHR P16473 1/20 0.39
LMNA P02545 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1602748 0.84 NFKB1 (0.46) NFKB1NFKB2RELAJUNXPO1
SCHEMBL30110408 0.84 NFKB1 (0.46) NFKB1NFKB2RELAJUNXPO1
SCHEMBL31391972 0.83 RAB9A (0.53) NFKB1NFKB2RELAJUNSMN1; SMN2
SCHEMBL3435395 0.83 RAB9A (0.53) NFKB1NFKB2RELAJUNSMN1; SMN2
SCHEMBL8590367 0.81 RAB9A (0.47) NFKB1NFKB2RELAJUNSMN1; SMN2
SCHEMBL31584477 0.81 TSHR (0.45) NFKB1NFKB2RELAJUNSMN1; SMN2
SCHEMBL21554055 0.81 TSHR (0.45) NFKB1NFKB2RELAJUNSMN1; SMN2
SCHEMBL3056707 0.79 NFKB1 (0.55) NFKB1NFKB2RELAJUNXPO1
SCHEMBL16543696 0.79 NFKB1 (0.59) NFKB1NFKB2RELAJUNXPO1
SCHEMBL63532 0.79 HPGD (0.58) NFKB1NFKB2RELAJUNXPO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106565717-A Synthetic method of medicine raw material methyl 2,5-difluoro-6-ethylpurine-5-carboxylate 无锡乾浩生物医药有限公司 2017-04-19 CN claimed
US-12459927-B2 Plasma kallikrein inhibitors MERCK SHARP & DOHME LLC (US) 2025-11-04 US disclosed
CN-115989224-B Plasma kallikrein inhibitors 默沙东有限责任公司 2025-02-25 CN disclosed
US-20230286958-A1 PLASMA KALLIKREIN INHIBITORS MERCK SHARP & DOHME LLC (US) 2023-09-14 US disclosed
US-20230286958-A1 PLASMA KALLIKREIN INHIBITORS MERCK SHARP & DOHME LLC (US) 2023-09-14 US disclosed
US-11672251-B2 Herbicidally active pyridyl-/pyrimidyl-pyrimidine derivatives SYNGENTA PARTICIPATIONS AG (CH) 2023-06-13 US disclosed
EP-4164634-A1 PLASMA KALLIKREIN INHIBITORS Merck Sharp & Dohme LLC (US) 2023-04-19 EP disclosed
CN-115989224-A Plasma kallikrein inhibitors 默沙东有限责任公司 2023-04-18 CN disclosed
EP-3863713-B1 PHENYLTETRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2023-01-25 EP disclosed
WO-2021257353-A1 PLASMA KALLIKREIN INHIBITORS MERCK SHARP & DOHME CORP. (US) 2021-12-23 WO disclosed
WO-2021257353-A1 PLASMA KALLIKREIN INHIBITORS MERCK SHARP & DOHME CORP. (US) 2021-12-23 WO disclosed
US-20200267981-A1 Herbicidally Active Pyridyl-/Pyrimidyl-Pyrimidine Derivatives SYNGENTA PARTICIPATIONS AG (CH) 2020-08-27 US disclosed
WO-2020035540-A1 HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2020-02-20 WO disclosed
CN-110267954-A 1,2- pyrrolin simultaneously [3,4-c] pyridine/pyrimidine -3- ketone derivatives and the purposes that aniline replaces 上海海雁医药科技有限公司 2019-09-20 CN disclosed
CN-106565717-A Synthetic method of medicine raw material methyl 2,5-difluoro-6-ethylpurine-5-carboxylate 无锡乾浩生物医药有限公司 2017-04-19 CN disclosed
CN-101663302-B Nitrogenated fused ring derivative, pharmaceutical composition comprising the same, and use of the same for medical purposes KISSEI PHARMACEUTICAL 2013-07-24 CN disclosed
CN-101663302-A Nitrogenated fused ring derivative, pharmaceutical composition comprising the same, and use of the same for medical purposes KISSEI PHARMACEUTICAL 2010-03-03 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230286958-A1 PLASMA KALLIKREIN INHIBITORS KLKB1, SERPINE1, KLK5 NFKB1 712/4885NFKB2 1214/4885RELA 1972/4885
US-20200267981-A1 Herbicidally Active Pyridyl-/Pyrimidyl-Pyrimidine Derivatives PLPBP, PDXK, DPYD NFKB1 3880/4885NFKB2 4605/4885RELA 4593/4885
US-12459927-B2 Plasma kallikrein inhibitors KLKB1, SERPINE1, KLK5 NFKB1 712/4885NFKB2 1214/4885RELA 1972/4885
US-11672251-B2 Herbicidally active pyridyl-/pyrimidyl-pyrimidine derivatives PLPBP, PDXK, DPYD NFKB1 3880/4885NFKB2 4605/4885RELA 4593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.